Phase 4 N=14 Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study
Coronary Artery Disease
Primary: P2Y12 Reaction Unit (PRU) — 5; 24 PRU — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=77 Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
Schizophrenia · Metabolic Syndrome X · Insulin Resistance
Primary: Change in Insulin Sensitivity Index From Baseline to Week 26 ((1/mU/L) x 1/Min) — 0.072; 0.407 (1/mU/L) x 1/Min — p=0.228
Phase 4 N=80 Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease
Coronary Artery Disease
Primary: Platelet Reactivity Unit — 177; 164; 174; 26 PRU — p=>0.05
Phase 4 N=65 A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:
Coronary Artery Disease
Primary: Platelet Reactivity — 36; 33 PRU
Phase 4 N=172 Acthar Gel for Active Systemic Lupus Erythematosus (SLE)
Lupus Erythematosus, Systemic
Primary: Physician's Global Assessment (PGA) — 58.8; 60.6; 33.2; 30.2 score on a scale
Phase 4 N=60 Transdermal Nicotine and Melatonin Patches for Postoperative Pain Relief
Postoperative Pain Relief
Primary: A Mean Difference of Total Analgesic (Pethidine) Consumption. — 122.15; 55.5; 59.7 mg
Phase 4 N=327 Oral Versus Intravenous Sedation for Ocular Procedures
Surgery · Sedation
Primary: Patient Satisfaction — 5.37; 5.23; 5.37; 5.05 score on a scale — p=<0.05
Phase 4 N=28 Copper IUD Treatment Observation Study
Menorrhagia
Primary: Mean Days of Bleeding and Spotting, Spotting Only and Bleeding Only for the 84 Day Treatment Cycles and Last 28 Day Post-treatment Cycle — 29.2; 23.0; 9.3; 9.6 days…
Phase 4 N=22 Special Access Program IMVAMUNE®
Vaccination
Primary: ELISA Seropositivity Rate — 40.9; 100.0 percentage of subjects
Phase 4 N=7,119 Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
Cardiovascular Disease · Interventional Cardiology
Primary: Number of Participants With BARC Type 2, 3, or 5 — 141; 250 Participants
Phase 4 N=32 CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
HIV Infections
Primary: Differences in Gene Expression Profiles Obtained at Baseline and Week 4 and Week 24. — 1.44 -fold TNF downregulation
Phase 4 N=251 Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy
Epilepsy, Partial
Primary: Number of Patients With Adverse Events (AEs) — 184 Participants
Phase 4 N=67 Infiltration Analgesia After Caesarean Section
Pain, Postoperative · Caesarean Section
Primary: The Demand of Rescue Analgesics (Oxycodone) — 47.5; 57.8 mg — p=0.10
Phase 4 N=87 Prophylaxis of Periprosthetic Joint Infections With Calcium Sulfate Beads in Patients With Non-modifiable Risk Factors.
Infection
Primary: Partipants Achieving a Lower Hip or Knee Periprosthetic Joint Infection Rate With Local Versus Conventional Intravenous Antibiotic Prophilaxys, Measured With CRP, ERS in…
Phase 4 N=165 Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients
Type 2 Diabetes Mellitus
Primary: The Change of Glycated Hemoglogin(HbA1c) From Baseline to 16 Weeks of Treatment — -0.09; -0.44; 0.84 % of HbA1c — p=0.0036